Elabela as a novel marker: Well-correlated with WIfI amputation risk score in lower extremity arterial disease patients
| Autor: | Kaplan, Mehmet, Yavuz, Fethi, Kaplan, Gizem Ilgın, Bursa, Nurbanu, Vuruşkan, Ertan, Sucu, Murat |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Time Factors
Limb Salvage Risk Assessment Amputation Surgical Decision Support Techniques Peripheral Arterial Disease Cross-Sectional Studies Treatment Outcome Lower Extremity Predictive Value of Tests Risk Factors RC666-701 Humans Diseases of the circulatory (Cardiovascular) system Original Investigation Retrospective Studies |
| Zdroj: | Anatolian Journal of Cardiology, Vol 25, Iss 5, Pp 330-337 (2021) Anatol J Cardiol |
| ISSN: | 2149-2271 2149-2263 |
| Popis: | OBJECTIVE: Worldwide, over 200 million people are diagnosed with lower extremity arterial disease (LEAD). LEAD significantly increases the risk of death and amputation of the lower limb. A new classification system (WIfI) has been proposed to initially assess all patients with ischemic rest pain or wounds and also predicts 1-year amputation risk. Elabela is a bioactive peptide and a part of the apelinergic system, which has beneficial effects on body fluid homeostasis and cardiovascular health. We aimed to investigate serum Elabela levels in LEAD. METHODS: A total of 119 subjects were enrolled in this cross-sectional study, 60 of whom were in the LEAD group and 59 in the control group. All participants underwent physical examination and routine biochemical tests, including serum Elabela levels. Additionally, the LEAD group was divided into subgroups according to the Rutherford classification, ankle-brachial index (ABI) values, and WIfI risk scores. RESULTS: Serum low-density lipoprotein, Elabela, and high-sensitivity C-reactive protein (Hs-CRP) levels were statistically higher in the LEAD group (p=0.002, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|